Modality
Vaccine
MOA
BTKi
Target
GPRC5D
Pathway
Checkpoint
FSGS
Development Pipeline
Preclinical
Jan 2017
→ Mar 2025
PreclinicalCurrent
NCT04475173
1,716 pts·FSGS
2017-01→2025-03·Active
1,716 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-03-041.1y agoInterim· FSGS
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2
Preclinical
Active
Catalysts
Interim
2025-03-04 · 1.1y ago
FSGS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04475173 | Preclinical | FSGS | Active | 1716 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 |